following a full submission
tinzaparin (Innohep Syringe®) is accepted for use within NHS Scotland.
Indication under review: Patients with solid tumours: Extended treatment of symptomatic venous thrombo-embolism (VTE) and prevention of its recurrence.
In patients with cancer and VTE, tinzaparin was associated with rates of VTE recurrence that were not significantly different from those with a vitamin K antagonist (VKA). In a large study it was not significantly different from a VKA for a composite outcome that included symptomatic deep vein thrombosis (DVT), non-fatal and fatal pulmonary embolism (PE), incidental DVT and PE.
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of tinzaparin. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice170KB (PDF)
Medicine details
- Medicine name:
- tinzaparin sodium (Innohep)
- SMC ID:
- 1061/15
- Indication:
- Patients with solid tumours: Extended treatment of symptomatic venous thrombo-embolism (VTE) and prevention of its recurrence.
- Pharmaceutical company
- LEO Pharmaceuticals
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 July 2015